Sepsia Therapeutics is a pioneering brand dedicated to combating sepsis, a life-threatening condition caused by the body's response to infectious agents. With a mission to develop innovative and effective therapies, Sepsia Therapeutics focuses on broad-spectrum biological and cellular treatments. Through extensive research, they have identified host receptors found on lymphocyte cell surfaces that bind to and neutralize the inflammation-promoting structures of bacteria and fungi responsible for sepsis.

By targeting both microbial virulence factors and host inflammatory and immune mediators, Sepsia Therapeutics aims to address the urgent need for alternative sepsis treatments. With the incidence of sepsis on the rise globally, the emergence of multidrug-resistant organisms adds to the urgency of their work. Sepsia Therapeutics offers a new perspective on fighting infectious agents, utilizing non-antibiotic approaches such as biological infusion, adoptive cell transfer, and medical devices for toxin removal.

Their products include SIXTIDE, a cutting-edge anti-sepsis drug that undergoes rigorous preclinical and clinical trials, targeting the pro-inflammatory properties of microbial cell structures. By harnessing the power of human scavenger-receptors, Sepsia Therapeutics aims to transform the current paradigm and provide a novel and effective solution to combat sepsis and its devastating outcomes. Contact Sepsia Therapeutics today to learn more about their groundbreaking advancements in infection and inflammation treatment